News
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback